{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:45:04Z","timestamp":1790610304790,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020549","name":"Centre Leon Berard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejca.2022.10.023","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T20:06:30Z","timestamp":1668024390000},"page":"114-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010\u201302)"],"prefix":"10.1016","volume":"178","author":[{"given":"S\u00e9verine","family":"Racadot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Thennevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaelle","family":"Ouldbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-5160","authenticated-orcid":false,"given":"Marie-Christine","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"de Raucourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Alfonsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Malaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3884-6816","authenticated-orcid":false,"given":"Pierre","family":"Fournel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Vauleon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouchka","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0894","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dussart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2022.10.023_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ejca.2022.10.023_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2022.10.023_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/annonc\/mdx304","article-title":"Human papillomavirus-related oropharyngeal cancer","volume":"28","author":"Taberna","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.10.023_bib4","series-title":"TNM classification of malignant tumours","first-page":"20171","author":"Brierley","year":"2017"},{"issue":"Suppl 7","key":"10.1016\/j.ejca.2022.10.023_bib5","doi-asserted-by":"crossref","first-page":"S1299","DOI":"10.21037\/tcr.2017.10.04","article-title":"Patterns of failure in head and neck cancer patients treated with intensity modulated radiation therapy: editorial response","volume":"6","author":"Leeman","year":"2017","journal-title":"Transl Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2022.10.023_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC\u00a0(#22931) and RTOG (#9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"issue":"19","key":"10.1016\/j.ejca.2022.10.023_bib7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2022.10.023_bib8","first-page":"203","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"9","author":"Bernier","year":"2005","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ejca.2022.10.023_bib9","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1016\/j.annonc.2020.08.1029","article-title":"Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): results of the GORTEC 2015-02 CisFRad randomized trial","volume":"31","author":"Borel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.10.023_bib10","doi-asserted-by":"crossref","first-page":"E2151","DOI":"10.1002\/hed.24026","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review","volume":"38","author":"Strojan","year":"2016","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.ejca.2022.10.023_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.10.023_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.10.023_bib13","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1158\/0008-5472.CAN-08-2881","article-title":"The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma","volume":"69","author":"Seiwert","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2022.10.023_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdu216","article-title":"A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"25","author":"Seiwert","year":"2014","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2022.10.023_bib15","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-12-1518","article-title":"Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02)","volume":"18","author":"Thariat","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.ejca.2022.10.023_bib16","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2015.61.4370","volume":"33","author":"Harrington","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.10.023_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","article-title":"NCCN guidelines \u00ae insights: head and neck cancers, version 1.2018 featured updates to the NCCN guidelines","volume":"16","author":"Colevas","year":"2018","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"issue":"Supplement 5","key":"10.1016\/j.ejca.2022.10.023_bib18","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.10.023_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.tps197","article-title":"EORTC 22071-24071: randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence","volume":"29","author":"Liberatoscioli","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.10.023_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e21134","article-title":"Efficacy and safety of afatinib in advanced non-small cell lung cancer with EGFR mutations: a real-world study based meta-analysis","volume":"39","author":"Zhang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.10.023_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40267-018-0482-6","article-title":"Afatinib in advanced NSCLC: a profile of its use","volume":"34","author":"Deeks","year":"2018","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.ejca.2022.10.023_bib22","unstructured":"ICRU Report 62. https:\/\/www.icru.org\/report\/prescribing-recording-and-reporting-photon-beam-therapy-report-62\/."},{"issue":"5","key":"10.1016\/j.ejca.2022.10.023_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2022.10.023_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.3.1008","article-title":"Quality of life in head and neck cancer patients: validation of the European organization for research and treatment of cancer quality of life questionnaire-H&N35","volume":"17","author":"Bjordal","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.10.023_bib25","series-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"issue":"8","key":"10.1016\/j.ejca.2022.10.023_bib26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaoncol.2019.1146","article-title":"Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck: a randomized clinical trial","volume":"5","author":"Burtness","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.10.023_bib27","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdw151","article-title":"Afatinib versus methotrexate in older patients with second-line recurrent and\/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial","volume":"27","author":"Clement","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.10.023_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.10.023_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2019.04.034","article-title":"A phase 1 study of afatinib in combination with postoperative radiation therapy with and without weekly docetaxel in intermediate- and high-risk patients with resected squamous cell carcinoma of the head and neck","volume":"105","author":"Margalit","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.10.023_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.10.023_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis\u00a0of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922013260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922013260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:07Z","timestamp":1760733547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922013260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":31,"alternative-id":["S0959804922013260"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010\u201302)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}